DOI . ORG {}

Analyzed Page
Matching Content Categories
CMS
Monthly Traffic Estimate
How Does Doi.org Make Money
Keywords
Topics
Schema
External Links
Analytics And Tracking
Libraries
Hosting Providers
CDN Services

We began analyzing https://link.springer.com/article/10.1007/s002620050415, but it redirected us to https://link.springer.com/article/10.1007/s002620050415. The analysis below is for the second page.

Title[redir]:
Tumor-specific T-bodies: towards clinical application | Cancer Immunology, Immunotherapy
Description:
Unlike antibodies, T cells are well suited to penetrate and destroy solid tumors. The T-body approach combines antibody recognition and T cells effector function. It is based on T cells expressing chimeric receptors composed of antibody-derived Fv or scFv as their extracellular recognition elements joined to lymphocyte triggering molecules. This receptors can redirect the specificity of T cells in an MHC independent manner. Upon encountering their target cells, T-bodies are able to undergo specific stimulation for interleukin/cytokine production, and kill hapten-modified or tumor cells in model systems both in vitro and in vivo. T cells expressing chimeric receptors made of antitumor antibodies are able to discriminate between a tumor and normal cell with negligible bystander cytotoxicity. Further studies should be carried out to evaluate and optimize the persistence, homing patterns and reactivation potential of T-bodies in the body.

Matching Content Categories {📚}

Science
Mobile Technology & AI
Virtual Reality

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🏙️ Massive Traffic: 50M - 100M visitors per month

Based on our best estimate, this website will receive around 80,479,999 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

The income method remains a mystery to us.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Doi.org might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

article, cells, privacy, cookies, content, tbodies, access, information, publish, search, cancer, clinical, therapy, data, log, journal, research, immunology, immunotherapy, tumorspecific, application, eshhar, antibodies, receptors, discover, springer, function, optional, personal, parties, policy, find, track, november, cite, zelig, explore, antibody, recognition, expressing, chimeric, specificity, tumor, cell, potential, institution, open, tcell, chapter, related,

Topics {✒️}

tumor-specific t-bodies access tumor-specific t-bodies month download article/chapter 2024 t-cell immunotherapy antibody-derived fv privacy choices/manage cookies article cancer immunology undergo specific stimulation full article pdf cell therapy article eshhar european economic area destroy solid tumors lymphocyte triggering molecules mhc independent manner interleukin/cytokine production negligible bystander cytotoxicity related subjects conditions privacy policy kill hapten-modified t-bodies cells effector function accepting optional cookies journal finder publish antitumor antibodies clinical application tumor cells normal cell check access instant access article log privacy policy personal data immunotherapy aims books a therapy target cells optional cookies manage preferences november 1997 volume 45 article cite subscription content similar content data protection essential cookies cookies skip institution subscribe journal publish usage analysis social media

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Tumor-specific T-bodies: towards clinical application
         description: Unlike antibodies, T cells are well suited to penetrate and destroy solid tumors. The T-body approach combines antibody recognition and T cells effector function. It is based on T cells expressing chimeric receptors composed of antibody-derived Fv or scFv as their extracellular recognition elements joined to lymphocyte triggering molecules. This receptors can redirect the specificity of T cells in an MHC independent manner. Upon encountering their target cells, T-bodies are able to undergo specific stimulation for interleukin/cytokine production, and kill hapten-modified or tumor cells in model systems both in vitro and in vivo. T cells expressing chimeric receptors made of antitumor antibodies are able to discriminate between a tumor and normal cell with negligible bystander cytotoxicity. Further studies should be carried out to evaluate and optimize the persistence, homing patterns and reactivation potential of T-bodies in the body.
         datePublished:
         dateModified:
         pageStart:131
         pageEnd:136
         sameAs:https://doi.org/10.1007/s002620050415
         keywords:
            Key words: Tumor-specific T-bodies
            Oncology
            Immunology
            Cancer Research
         image:
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:45
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Zelig Eshhar
               affiliation:
                     name:The Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel Phone: 972-8–9343965 Fax: 972-8–9344141 e-mail: [email protected]
                     address:
                        name:The Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel Phone: 972-8–9343965 Fax: 972-8–9344141 e-mail: [email protected], , IL
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Tumor-specific T-bodies: towards clinical application
      description: Unlike antibodies, T cells are well suited to penetrate and destroy solid tumors. The T-body approach combines antibody recognition and T cells effector function. It is based on T cells expressing chimeric receptors composed of antibody-derived Fv or scFv as their extracellular recognition elements joined to lymphocyte triggering molecules. This receptors can redirect the specificity of T cells in an MHC independent manner. Upon encountering their target cells, T-bodies are able to undergo specific stimulation for interleukin/cytokine production, and kill hapten-modified or tumor cells in model systems both in vitro and in vivo. T cells expressing chimeric receptors made of antitumor antibodies are able to discriminate between a tumor and normal cell with negligible bystander cytotoxicity. Further studies should be carried out to evaluate and optimize the persistence, homing patterns and reactivation potential of T-bodies in the body.
      datePublished:
      dateModified:
      pageStart:131
      pageEnd:136
      sameAs:https://doi.org/10.1007/s002620050415
      keywords:
         Key words: Tumor-specific T-bodies
         Oncology
         Immunology
         Cancer Research
      image:
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:45
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Zelig Eshhar
            affiliation:
                  name:The Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel Phone: 972-8–9343965 Fax: 972-8–9344141 e-mail: [email protected]
                  address:
                     name:The Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel Phone: 972-8–9343965 Fax: 972-8–9344141 e-mail: [email protected], , IL
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:45
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:The Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel Phone: 972-8–9343965 Fax: 972-8–9344141 e-mail: [email protected]
      address:
         name:The Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel Phone: 972-8–9343965 Fax: 972-8–9344141 e-mail: [email protected], , IL
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Zelig Eshhar
      affiliation:
            name:The Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel Phone: 972-8–9343965 Fax: 972-8–9344141 e-mail: [email protected]
            address:
               name:The Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel Phone: 972-8–9343965 Fax: 972-8–9344141 e-mail: [email protected], , IL
               type:PostalAddress
            type:Organization
PostalAddress:
      name:The Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel Phone: 972-8–9343965 Fax: 972-8–9344141 e-mail: [email protected], , IL
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(58)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

Emails and Hosting {✉️}

Mail Servers:

mx.zoho.eu
mx2.zoho.eu
mx3.zoho.eu

Name Servers:

josh.ns.cloudflare.com
zita.ns.cloudflare.com

CDN Services {📦}

Crossref

4.94s.